

Bronson Healthcare

2019-20 (Two-Year) Antibiotic Activity Summary

Antibiogram

BMH Pediatric Units (PED, PICU, NICU)

Percent of strains susceptible:

Gram Negative Enteric Bacteria	No. Tested	Ampicillin/Sulbactam	Piperacillin/tazobactam	Aztreonam	Cefazolin	Cefoxitin	Ceftriaxone	Cefepime	Meropenem	Gentamicin	Tobramycin	Amikacin	Levofloxacin	Sulfa/Trimethoprim	Nitrofurantoin	Tetracycline
<i>Escherichia coli</i>	61	43	98	97	95	97	97	97	100	87	93	100	92	66	95	82

Gram Negative Non-enteric Bacteria	No. Tested	Piperacillin/tazobactam	Cefepime	Meropenem	Aztreonam	Gentamicin	Tobramycin	Amikacin	Levofloxacin
<i>Pseudomonas aeruginosa</i>	37	100	92	95	60	89	100	95	86

Staphylococci	No. Tested	Penicillin/ampicillin	Oxacillin/nafcillin	Erythromycin	Clindamycin	Gentamicin	Levofloxacin	Sulfa/Trimethoprim	Vancomycin	Rifampin*	Tetracycline	Minocycline	Linezolid	Nitrofurantoin
<i>Staphylococcus aureus</i>	139	R	80	52	80	99	87	99	100	99	96	100	100	100

*Rifampin should be used only in combination with another agent

R denotes intrinsic resistance

Dosing recommendations are generalized; dosing should be optimized for each patient.

Adam Warner, PharmD
 Antimicrobial Stewardship Pharmacist
 (269) 341-6230
warnera@bronsonhq.org

Richard A. Van Enk, Ph.D.
 Epidemiologist
 (269) 341-6316
vanenkr@bronsonhq.org

Eric Parnell
 Laboratory Supervisor
 (269) 341-8845
parnelle@bronsonhq.org